NICE recommends Takeda’s Adcetris for previously untreated systemic anaplastic large cell lymphoma

pharmafile | July 9, 2020 | News story | Sales and Marketing Adcentris, NICE, Takeda, UK 

NICE has announced it has recommended Takeda’s Adcetris (brentuximab vedotin), in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL), a rare form of non-Hodgkin lymphoma.

Standard of care for sALCL has included offering patients CHP in addition to vincristine, but this has been associated with difficult side-effects. Takeda’s drug, when offered alongside CHP, has been shown to reduce the prevalence of these side-effects.

On top of this, clinical data submitted to NICE supports the combo therapy’s survival benefit, showing that patients receiving the combo were almost twice as likely to still be alive after a five-year evaluation period compared to those receiving CHP plus vincristine.

With the decision, around 191 of the approximately 273 patients in England with sALCL are expected to be eligible to receive the combo, which will replace CHP plus vincristine in untreated forms of the disease.   

The agreement between NICE and Takeda means that the drug will be mafe available on the NHS at a confidential discount. The treatment usually costs £2,500 per vial, with the total cost of treatment per patient estimated at £47,619 per patient based on an average of six treatment cycles.  

Matt Fellows

Related Content

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended …

Latest content